Brazil to announce more efficacy data of Sinovac's vaccine
Brazilian biomedical center Butantan will announce the average efficacy of the CoronaVac vaccine on Tuesday in a press conference, Sao Paulo state health secretary Jean Gorinchteyn said in an interview to GloboNews TV.
The vaccine, by China's Sinovac Biotech, was 78% effective in a late-stage Brazilian trial with no severe COVID-19 cases, researchers said on Jan. 7. But they did not disclose full trial details including the average efficacy.
ALSO READ
-
More Than Shorter Commute: How Compact Cities Can Help Migrant Workers Find Jobs
-
ILO Report Reveals How to Bring Social Security Within Reach of Informal Workers
-
WTO Sets Up Panel on EU Carbon Border Rules as Russia Challenges Restrictions
-
WHO Brings Global Experts Together to Strengthen Herbal Medicine Quality and Safety
-
Human Cost of Faster Work: Chinese Employees Weigh AI’s Promise Against Pay Fears
Google News